NCT07485881Not yet recruiting
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
18F-PSMA PET/CT Versus CT Alone in Initial Staging, Assessment of Therapy Response and Evaluation of Biochemical Recurrence in Prostatic Cancer Patients
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
To compare the diagnostic performance of 18-F PSMA PET/CT and CT alone in initial staging, assessment of therapy response, as well as evaluation of biochemical recurrence of prostatic cancer patients The main question it aims to answer is: Does 18-F PSMA PET/CT have a superior role over CT in evaluation of prostatic cancer patients?
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 59 (estimated)
- First submitted
- 17 Mar 2026
- Start date
- 1 May 2026
- Primary completion date
- May 2028
- Lead sponsor
- Assiut University
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT07485881
What you commit to
- Study type: Observational
- Planned participants: 59
- From 1 May 2026 to the primary completion date, May 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with claustrophobia
- Patients refuse to do the scan
Who the study is looking for
- Patients with known prostate cancer referred for 18-F PSMA PET/CT study
Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.